Fluoxetine protects against monocrotaline-induced pulmonary arterial hypertension: Potential roles of induction of apoptosis and upregulation of kv1.5 channels in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 8, 2009, Pages 850-856

  Zhai, Feng Guo ^a,b   Zhang, Xin Hua ^a   Wang, Huai Liang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Mudanjing Medical College   (China)

Author keywords

Apoptosis; Fluoxetine; Kv channel; Monocrotaline; Pulmonary arterial hypertension; Selective serotonin reuptake inhibitor; Serotonin transporter

Indexed keywords

CASPASE 3; FLUOXETINE; MESSENGER RNA; MONOCROTALINE; POTASSIUM CHANNEL KV1.5; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL WALL THICKNESS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMICS; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; TREATMENT DURATION; UPREGULATION; WISTAR RAT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOXETINE; HYPERTENSION, PULMONARY; KV1.5 POTASSIUM CHANNEL; LUNG; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; PULMONARY CIRCULATION; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; UP-REGULATION;

EID: 68549112957     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05168.x     Document Type: Article

References (44)

1. Guibert C, Marthan R, Savineau JP. Modulation of ion channels in pulmonary arterial hypertension. Curr. Pharm. Des. 2007 13 : 2443 55.
2. MacLean MR. Pulmonary hypertension and the serotonin hypothesis: Where are we now? Int. J. Clin. Pract. Suppl. 2007 156 : 27 31.
3. Archer S, Rich S. Primary pulmonary hypertension: A vascular biology and translational research 'work in progress'. Circulation 2000 102 : 2781 91.
4. Zhang S, Fantozzi I, Tigno DD et al. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2003 285 : L740 54.
5. McMurtry MS, Bonnet S, Wu X et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 2004 95 : 830 40.
6. Lagna G, Nguyen PH, Ni W, Hata A. BMP-dependent activation of caspase-9 and caspase-8 mediates apoptosis in pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 2006 291 : L1059 67.
7. Nishimura T, Vaszar LT, Faul JL et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003 108 : 1640 5.
8. (Kv) and enhances apoptosis. Am. J. Physiol. Cell Physiol. 2004 287 : C715 22.
9. McMurtry MS, Archer SL, Altieri DC et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 2005 115 : 1479 91.
10. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005 112 : 423 31.
11. 2A receptors, caveolin-1, and Kv1.5 channel internalization. Circ. Res. 2006 98 : 931 8.
12. i in pulmonary arterial myocytes. Circ. Res. 1995 77 : 370 8.
13. Burg ED, Remillard CV, Yuan JX. Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: Pharmacotherapeutic implications. Br. J. Pharmacol. 2008 153 (Suppl. 1 S99 111.
14. Bonnet S, Rochefort G, Sutendra G et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl Acad. Sci. USA 2007 104 : 11 418 23.
15. Remillard CV, Tigno DD, Platoshyn O et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am. J. Physiol. Cell Physiol. 2007 292 : C1837 53.
16. Bonnet S, Michelakis ED, Porter CJ et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: Similarities to human pulmonary arterial hypertension. Circulation 2006 113 : 2630 41.
17. Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J. Mol. Cell. Cardiol. 2008 44 : 14 30.
18. Wang HL. The serotonin receptor and transporter are potential therapeutic targets for pulmonary hypertension. Curr. Opin. Invest. Drugs 2004 5 : 963 6.
19. Eddahibi S, Hanoun N, Lanfumey L et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest 2000 105 : 1555 62.
20. Eddahibi S, Humbert M, Fadel E et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 2001 108 : 1141 50.
21. Marcos E, Fadel E, Sanchez O et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ. Res. 2004 94 : 1263 70.
22. Slattery DA, Hudson AL, Nutt DJ. The evolution of antidepressant mechanisms. Fundam. Clin. Pharmacol. 2004 18 : 1 21.
23. Song D, Wang HL, Wang S, Zhang XH. 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol. Sin. 2005 26 : 563 7.
24. Marcos E, Adnot S, Pham MH et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003 168 : 487 93.
25. Guignabert C, Raffestin B, Benferhat R et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005 111 : 2812 19.
26. Li XQ, Hong Y, Wang Y, Zhang XH, Wang HL. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin. Exp. Pharmacol. Physiol. 2006 33 : 1047 51.
27. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 2000 6 : 698 702.
28. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 2001 163 : 737 44.
29. Geraci MW, Moore M, Gesell T et al. Gene expression patterns in the lungs of patients with primary pulmonary hypertension: A gene microarray analysis. Circ. Res. 2001 88 : 555 62.
30. Yang C, Wang S, Liang T, Wang J, Wang K, Wang B. The roles of bcl-2 gene family in the pulmonary artery remodeling of hypoxia pulmonary hypertension in rats. Chin. Med. Sci. J. 2001 16 : 182 4.
31. Suzuki YJ, Nagase H, Wong CM et al. Regulation of Bcl-xL expression in lung vascular smooth muscle. Am. J. Respir. Cell. Mol. Biol. 2007 36 : 678 87.
32. Jankov RP, Kantores C, Belcastro R, Yi M, Tanswell AK. Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr. Res. 2006 60 : 245 51.
33. Li F, Xia W, Li A, Zhao C, Sun R. Long-term inhibition of Rho kinase with fasudil attenuates high flow induced pulmonary artery remodeling in rats. Pharmacol. Res. 2007 55 : 64 71. (Pubitemid 46108589)
34. Fagan KA, Oka M, Bauer NR et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 2004 287 : L656 64.
35. Nagaoka T, Morio Y, Casanova N et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol. 2004 287 : L665 72.
36. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 2004 94 : 385 93.
37. + channel gene transcription in primary pulmonary hypertension. Lancet 1998 351 : 726 7.
38. Michelakis ED, McMurtry MS, Wu XC et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 2002 105 : 244 50.
39. Young KA, Ivester C, West J, Carr M, Rodman DM. BMP signaling controls PASMC Kv channel expression in vitro and in vivo. Am. J. Physiol. Lung Cell Mol. Physiol. 2006 290 : L841 8.
40. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 2003 107 : 2037 44.
41. Guignabert C, Izikki M, Tu LI et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ. Res. 2006 98 : 1323 30.
42. Platoshyn O, Golovina VA, Bailey CL et al. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am. J. Physiol. Cell Physiol. 2000 279 : C1540 9.
43. Archer SL, London B, Hampl V et al. Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. FASEB J. 2001 15 : 1801 3.
44. Eddahibi S, Fabre V, Boni C et al. Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cell: Relationship with the mitogenic action of serotonin. Circ. Res. 1999 84 : 329 36.